Denosumab-induced cutaneous hypersensitivity reaction with distinct clinical and histopathologic findings

Targeted biologic agents are increasingly approved for the treatment of a wide range of medical conditions. Cutaneous drug reactions are seen to varying degrees with these agents, and postmarketing surveillance is critical to identifying adverse and uncommon events. Denosumab is a monoclonal antibody to receptor activator of nuclear factor kappa-B ligand (RANKL) that results in decreased osteoclast activation.